Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.
Addition Therapeutics has raised $100.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
Addition Therapeutics's investors include Bill & Melinda Gates Foundation, Abingworth, SR One, OUP (Osage University Partners), Pivotal Life Sciences.
Addition Therapeutics is headquartered in South San Francisco, United States.
Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.
Addition Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Addition Therapeutics — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/addition-therapeutics. Accessed July 31, 2026.
VCBacked. (2025). Addition Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/addition-therapeutics
{{cite web |title=Addition Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/addition-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated